Skip to main navigation
Skip to search
Skip to main content
Sort by
Keyphrases
Induction Therapy
100%
Antithymocyte Globulin
100%
OKT3
100%
Lung Transplantation
100%
Daclizumab
100%
Controlled Clinical Trial
100%
Bronchiolitis Obliterans Syndrome
83%
Acute Rejection
66%
Induction Agents
33%
Viral Infection
16%
Low Dose Rate
16%
Postoperative Outcomes
16%
No Significant Difference
16%
Patient Survival
16%
Non-infectious
16%
Long-term Survival
16%
First Year
16%
Bacterial Infection
16%
Length of Hospital Stay
16%
Low Risk
16%
Postoperative Infection
16%
Fungal Infection
16%
Ventilator
16%
2-year Survival
16%
ICU Stay
16%
Common Infections
16%
Acute Bronchiolitis
16%
Nursing and Health Professions
Lung Transplantation
100%
Thymocyte Antibody
100%
Clinical Trial
100%
Syndrome
83%
Bronchiolitis Obliterans
83%
Acute Graft Rejection
66%
Infection
50%
Anesthesia Induction
33%
Side Effect
33%
Postoperative Infection
16%
Long Term Survival
16%
Mycosis
16%
Virus Infection
16%
Immunosuppressive Treatment
16%
Bacterial Infection
16%
Graft Infection
16%
Economic and Social Development
16%
Medicine and Dentistry
Controlled Clinical Trial
100%
Lung Transplantation
100%
Thymocyte Antibody
100%
Daclizumab
100%
Bronchiolitis Obliterans
83%
Acute Graft Rejection
66%
Infection
50%
Anesthesia Induction
33%
Side Effect
33%
Virus Infection
16%
Immunosuppressive Treatment
16%
Long Term Survival
16%
Postoperative Infection
16%
Mycosis
16%
Bacterial Infection
16%
Graft Infection
16%
Immunology and Microbiology
Infectious Disease
100%
Anti-Thymocyte Globulin
100%
Daclizumab
100%
Lung Transplantation
100%
Infection
100%
Bronchiolitis
83%
Acute Graft Rejection
66%
Viral Disease
16%
Immunosuppression
16%
Long Term Survival
16%
Transplant Infection
16%
Pharmacology, Toxicology and Pharmaceutical Science
Controlled Clinical Trial
100%
Thymocyte Antibody
100%
Syndrome
83%
Bronchiolitis Obliterans
83%
Acute Graft Rejection
66%
Infection
50%
Side Effect
33%
Virus Infection
16%
Bacterial Infection
16%
Postoperative Infection
16%
Long Term Survival
16%
Mycosis
16%
Graft Infection
16%